StocksFundsScreenerSectorsWatchlists
KURA

KURA - Kura Oncology Inc Stock Price, Fair Value and News

21.32USD+0.15 (+0.71%)Delayed as of 28 Mar 2024, 11:04 am ET

Market Summary

KURA
USD21.32+0.15
Delayedas of 28 Mar 2024, 11:04 am
0.71%

KURA Stock Price

View Fullscreen

KURA RSI Chart

KURA Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-10.56

Price/Sales (Trailing)

109.48

Price/Free Cashflow

-12.9

KURA Price/Sales (Trailing)

KURA Profitability

Return on Equity

-38.42%

Return on Assets

-34%

Free Cashflow Yield

-7.75%

KURA Fundamentals

KURA Revenue

Revenue (TTM)

14.7M

Rev. Growth (Yr)

470.21%

Rev. Growth (Qtr)

12.41%

KURA Earnings

Earnings (TTM)

-152.6M

Earnings Growth (Yr)

-29.21%

Earnings Growth (Qtr)

-10.84%

Breaking Down KURA Revenue

52 Week Range

8.0021.57
(Low)(High)

Last 7 days

-4.2%

Last 30 days

3.8%

Last 90 days

56.3%

Trailing 12 Months

108.6%

How does KURA drawdown profile look like?

KURA Financial Health

Current Ratio

12.26

Debt/Equity

0.02

Debt/Cashflow

-13.38

KURA Investor Care

Shares Dilution (1Y)

11.25%

Diluted EPS (TTM)

-2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20236.8M9.4M014.7M
20221.2M1.5M2.3M4.3M
20212.0M01.5M1.3M
20205.0M4.8M4.0M2.9M
20193.7M4.1M4.5M4.9M
20181.0M1.5M2.4M3.2M
2017780.0K709.0K711.0K784.5K
20161.2M1.1M990.0K885.0K
2015001.2M1.2M
20140000

Tracking the Latest Insider Buys and Sells of Kura Oncology Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 30, 2024
dale stephen
sold
-103,980
21.5502
-4,825
chief medical officer
Jan 29, 2024
dale stephen
sold
-127,416
17.8005
-7,158
chief medical officer
Jan 29, 2024
bair teresa brophy
sold
-36,544
17.8005
-2,053
chief legal officer
Jan 29, 2024
doyle thomas james
sold
-41,261
17.8005
-2,318
svp, finance & accounting
Jan 29, 2024
ford kathleen
sold
-26,629
17.8005
-1,496
chief operating officer
Jan 24, 2024
wilson troy edward
sold
-1,841,980
20.23
-91,052
president and ceo
Jan 24, 2024
wilson troy edward
acquired
550,594
6.04703
91,052
president and ceo
Jan 02, 2024
doyle thomas james
acquired
-
-
21,250
svp, finance & accounting
Jan 02, 2024
bair teresa brophy
acquired
-
-
46,250
chief legal officer
Jan 02, 2024
powl brian t.
acquired
-
-
15,000
chief commercial officer

1–10 of 50

Which funds bought or sold KURA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
86.00
86.00
-%
Mar 11, 2024
VANGUARD GROUP INC
added
2.89
22,271,000
58,062,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
130
11,085,300
15,287,700
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
183,194
504,364
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-50.65
-70,000
248,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-101,000
-
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
281,857
770,553
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
1,413,770
1,413,770
-%
Feb 15, 2024
Virtus ETF Advisers LLC
reduced
-10.17
32,751
111,402
0.07%
Feb 15, 2024
ALETHEA CAPITAL MANAGEMENT, LLC
unchanged
-
1,843,340
5,039,400
5.81%

1–10 of 49

Are Funds Buying or Selling KURA?

Are funds buying KURA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KURA
No. of Funds

Unveiling Kura Oncology Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ecor1 capital, llc
9.99%
7,598,797
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
5.1%
3,801,949
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
9.99%
7,472,343
SC 13G/A
Feb 13, 2024
vanguard group inc
5.44%
4,037,691
SC 13G/A
Feb 12, 2024
flynn james e
7.15%
5,312,733
SC 13G/A
Jan 24, 2024
blackrock inc.
9.8%
7,315,647
SC 13G/A
Jan 23, 2024
state street corp
3.93%
2,921,810
SC 13G/A
Sep 21, 2023
flynn james e
5.89%
4,374,044
SC 13G
Feb 14, 2023
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
4.5%
3,105,000
SC 13G/A

Recent SEC filings of Kura Oncology Inc

View All Filings
Date Filed Form Type Document
Feb 29, 2024
UPLOAD
UPLOAD
Feb 27, 2024
10-K
Annual Report
Feb 27, 2024
8-K
Current Report
Feb 27, 2024
S-8
Employee Benefits Plan
Feb 15, 2024
424B3
Prospectus Filed
Feb 14, 2024
CORRESP
CORRESP
Feb 14, 2024
EFFECT
EFFECT
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
CORRESP
CORRESP

Peers (Alternatives to Kura Oncology Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Kura Oncology Inc News

Latest updates
InvestorsObserver • 47 hours ago
InvestorsObserver • 25 Mar 2024 • 03:53 pm
Defense World • 19 Mar 2024 • 09:13 am
MarketBeat • 17 Mar 2024 • 11:42 pm
Yahoo Finance • 01 Feb 2024 • 08:00 am

Kura Oncology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-100.0%-3,2162,8612,2711,0905643292953113103565598181,1191,4711,3961,0221,0301,0481,047624
Operating Expenses16.9%46,76240,00336,56635,15636,59435,33332,78233,03833,67730,89626,33224,19421,17320,20018,96317,67415,89114,95116,63415,98215,276
  S&GA Expenses20.4%14,22911,82111,37412,48811,62111,07511,86912,08211,31010,5728,8087,5937,4767,6255,4995,1344,4514,569---
  R&D Expenses15.4%32,53328,18225,19222,66824,97324,25820,91320,95622,36720,32417,52416,60113,69712,57513,46412,54011,44010,382---
Interest Expenses1.8%394387364------108144146144144142145148145193252267
Net Income-15.1%-42,786-37,174-34,069-33,114-35,504-34,769-32,453-32,743-33,366-30,694-26,159-23,769-20,487-19,210-17,865-16,392-14,943-13,940-16,097-15,007-14,739
Net Income Margin30.0%-10.37*-14.82*-20.26*-31.93*-59.47*-88.95*-97.76*-108.18*-83.42*-49.49*-----------
Free Cashflow-33.5%-34,324-25,713-35,908-26,542-21,391-30,525-32,230-23,468-25,317------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-5.2%449474495426456448471499534561585620647340353226242255266170182
  Current Assets-6.0%432460486416446436460487522549574611637329342221240253264168181
    Cash Equivalents29.8%37.0029.0049.0027.0052.0091.0039.0034.0091.0039.0039.0011132577.0013534.0026.0055.0012218.0016.00
  Net PPE-9.6%2.002.002.002.003.003.003.003.003.003.002.002.002.002.002.001.000.00----
Liabilities17.9%52.0044.0035.0031.0036.0028.0022.0022.0027.0027.0026.0034.0036.0033.0031.0023.0023.0021.0019.0020.0021.00
  Current Liabilities28.1%35.0028.0024.0019.0024.0025.0018.0018.0022.0022.0021.0025.0026.0022.0019.0015.0016.0013.0011.0012.0014.00
  Long Term Debt0.5%9.009.009.009.009.00------4.004.005.006.007.007.008.008.008.008.00
    LT Debt, Current------------3.003.003.002.001.000.00----
    LT Debt, Non Current0.5%9.009.009.009.009.00------4.004.005.006.007.007.008.008.008.008.00
Shareholder's Equity-7.6%397430460395420420449476507534559586611306322203219234247150161
  Retained Earnings-6.3%-721-678-640-602-568-535-500-465-432-400-366-333-302-276-252-232-212-195-178-163-149
  Additional Paid-In Capital0.7%1,1201,1121,1051,004997965957948941934926919913583574435431428425313311
Shares Outstanding0.1%74.0074.0074.0068.0068.0067.0067.0067.0066.0066.0066.0066.00---------
Float---777---1,200---1,300---878---822--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-18.2%-34,308-29,027-25,617-35,872-26,530-21,010-30,341-32,181-23,366-24,594-28,074-28,517-18,308-16,966-14,734-19,822-13,933-12,145-14,431-14,251-10,211
  Share Based Compensation1.1%7,1677,0906,9876,8386,8056,3556,5086,6506,3976,1145,9935,0753,7423,3602,5523,1532,4392,4522,2492,2691,716
Cashflow From Investing393.0%42,1958,559-46,32611,129-47,31871,81033,097-24,96274,06122,545-37,221-186,220-60,190-45,520-21,68727,461-15,257-55,7528,87615,8084,618
Cashflow From Financing722.6%69184.00--34,7138802,6693037942,258-6,56679.00327,0364,683137,368247583559109,8571021,144

KURA Income Statement

2023-12-31
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Expenses:   
Research and development$ 115,235$ 92,812$ 84,721
General and administrative50,56947,05346,537
Total operating expenses165,804139,865131,258
Other Income (Expense):   
Interest and other income, net14,7224,2541,206
Interest expense(1,549)(229)(414)
Total other income, net13,1734,025792
Net Loss$ (152,631)$ (135,840)$ (130,466)
Net loss per share, diluted$ (2.08)$ (2.03)$ (1.97)
Net loss per share, basic$ (2.08)$ (2.03)$ (1.97)
Weighted average number of shares used in computing net loss per share, basic73,22966,99066,352
Weighted average number of shares used in computing net loss per share, diluted73,22966,99066,352
Comprehensive Loss:   
Net loss$ (152,631)$ (135,840)$ (130,466)
Other comprehensive income (loss):   
Unrealized gain (loss) on marketable securities and foreign currency6,761(6,243)(1,835)
Comprehensive loss$ (145,870)$ (142,083)$ (132,301)

KURA Balance Sheet

2023-12-31
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 37,318$ 51,802
Short-term investments386,639386,183
Prepaid expenses and other current assets8,5248,441
Total current assets432,481446,426
Property and equipment, net1,8592,540
Operating lease right-of-use assets6,9933,842
Other long-term assets7,6023,498
Total assets448,935456,306
Current liabilities:  
Accounts payable and accrued expenses33,75721,739
Current operating lease liabilities1,5062,318
Total current liabilities35,26324,057
Long-term debt, net9,3329,158
Long-term operating lease liabilities6,3622,548
Other long-term liabilities705265
Total liabilities51,66236,028
Commitments and contingencies (Note 8)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000 shares authorized; 74,350 and 68,314 shares issued and outstanding as of December 31, 2023 and 2022, respectively77
Additional paid-in capital1,119,976997,111
Accumulated other comprehensive loss(1,271)(8,032)
Accumulated deficit(721,439)(568,808)
Total stockholders' equity397,273420,278
Total liabilities and stockholders' equity$ 448,935$ 456,306
KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
 CEO
 WEBSITEkuraoncology.com
 EMPLOYEES133

Kura Oncology Inc Frequently Asked Questions


What is the ticker symbol for Kura Oncology Inc? What does KURA stand for in stocks?

KURA is the stock ticker symbol of Kura Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kura Oncology Inc (KURA)?

As of Wed Mar 27 2024, market cap of Kura Oncology Inc is 1.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KURA stock?

You can check KURA's fair value in chart for subscribers.

What is the fair value of KURA stock?

You can check KURA's fair value in chart for subscribers. The fair value of Kura Oncology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kura Oncology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KURA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kura Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether KURA is over valued or under valued. Whether Kura Oncology Inc is cheap or expensive depends on the assumptions which impact Kura Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KURA.

What is Kura Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, KURA's PE ratio (Price to Earnings) is -10.56 and Price to Sales (PS) ratio is 109.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KURA PE ratio will change depending on the future growth rate expectations of investors.